Anupam Rasayan Q2 FY27 Revenue Up 11% to ₹821 Cr

Anupam Rasayan India Limited announced its unaudited financial results for Q2 and H1 FY27. For the quarter ended September 30, 2026, total revenue increased by 11% YoY to ₹821 Cr, with EBITDA up 41% YoY to ₹202 Cr and PAT up 14% YoY to ₹65 Cr. For the half-year ended September 30, 2026, total revenue grew 21% YoY to ₹1,489 Cr, EBITDA increased 38% YoY to ₹377 Cr, and PAT rose 10% YoY to ₹116 Cr. The company highlighted a six-year supply agreement with a US-based specialty metal manufacturer and the acquisition of a 50.07% stake in Bliss GVS Pharma. Management expressed confidence in building a diversified pharmaceutical platform and strengthening their specialty chemicals business.